Medicine information
उपयोग
LINALIGOLD 5 is an oral antidiabetic tablet marketed by Steris Healthcare, containing Linagliptin 5 mg. Linagliptin belongs to the DPP-4 inhibitor class of medicines and helps regulate blood glucose levels in adults with type 2 diabetes mellitus. Linagliptin works by inhibiting the DPP-4 enzyme, which increases the activity of incretin hormones. These hormones help stimulate insulin release in a glucose-dependent manner and reduce glucagon secretion when blood glucose levels are elevated. This mechanism supports blood glucose management as part of an individualized diabetes treatment plan. LINALIGOLD 5 may be prescribed alone or alongside other antidiabetic medicines, depending on the patient's medical condition and the treating physician's assessment. Maintaining a balanced diet, engaging in regular physical activity, and monitoring blood glucose as recommended are important components of diabetes care. The appropriate treatment plan should be determined by a qualified healthcare professional based on the patient's clinical condition, existing medicines, and response to treatment.
कैसे उपयोग करें
Take LINALIGOLD 5 exactly as prescribed by your doctor. Linagliptin is generally taken once daily, with or without food, according to the prescribed directions and approved product information. Swallow the tablet with water. Do not change the prescribed dose or discontinue treatment without consulting your healthcare professional. Continue following your recommended diet and exercise plan and monitor blood glucose as advised. Inform your doctor if you experience persistent discomfort, unexpected symptoms, or changes in your blood glucose levels.
भंडारण
Store LINALIGOLD 5 according to the instructions printed on the product packaging. Keep the tablets in their original packaging and protect them from excessive heat, moisture, and direct sunlight. Keep the medicine out of the reach of children. Do not use the tablets after their expiry date. Dispose of unused or expired medicine responsibly according to local pharmaceutical disposal guidance.
